Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 – 11 (Cancelled).

Claim 12 (Previously Presented): A method for treating a disease associated with HIV infection selected from the group consisting of Kaposi's sarcoma, thrombocytopenia purpurea, and an HIV related opportunistic infectious disease in humans comprising administering an effective amount of a β-D-nucleoside of the formula (I):

(I)



wherein R is hydrogen, acyl, monophosphate, diphosphate or triphosphate or a physiologically acceptable salt.

Claim 13 (Cancelled).

Claim 14 (Previously Presented): The method of claim 12, wherein the disease is Kaposi's sarcoma associated with HIV infection.

Claim 15 (Previously Presented): The method of claim 12, wherein the disease is thrombocytopenia purpurea associated with HIV infection.

Claim 16 (Previously Presented): The method of claim 12, wherein the disease is an HIV related opportunistic infectious disease associated with HIV infection.

Claim 17 (Previously Presented): The method of claim 12, wherein R is hydrogen.

Claim 18 (Previously Presented): The method of claim 12, wherein R is acyl.

Claim 19 (Previously Presented): The method of claim 12, wherein R is monophosphate.

Claim 20 (Previously Presented): The method of claim 12, wherein R is diphosphate.

Claim 21 (Previously Presented):. The method of claim 12, wherein R is triphosphate.

Claim 22 (Previously Presented): The method of claim 12, wherein the β –D nucleoside is administered in the form of an ester.

Claim 23 (Previously Presented): The method of claim 12, wherein the β –D nucleoside is administered in the form of a salt.

Claim 24 (Previously Presented): The method of claim 12, wherein the β –D isomer is at least 95% pure.

Claim 25 (Previously Presented): The method of claim 12, wherein the β-D-nucleoside is administered in a pharmaceutically acceptable carrier.

Claim 26 (Previously Presented): The method of claim 25, wherein the carrier is suitable for intravenous delivery.

Claim 27 (Previously Presented): The method of claim 25, wherein the carrier is suitable for parenteral delivery.

Claim 28 (Previously Presented): The method of claim 25, wherein the carrier is suitable for intradermal delivery.

Claim 29 (Previously Presented): The method of claim 25, wherein the carrier is suitable for subcutaneous delivery.

Claim 30 (Previously Presented): The method of claim 25, wherein the carrier is suitable for topical delivery.

Claim 31 (Previously Presented): The method of claim 25, wherein the carrier is suitable for oral delivery.

Claim 32 (Previously Presented): The method of claim 31, wherein the carrier is in the form of a tablet.

Claim ~~32~~ 33 (Currently Amended): The method of claim 25, wherein the β –D isomer is at least 95% pure.